ACIU News & Events

AC Immune SA announced the presentation of new preliminary data from a Phase 1 trial of its first-in-class TDP-43 positron emission tomography tracer ACI-19626 showing increased uptake in the brains of patients with amyotrophic lateral sclerosis. The results presented at the 2026 TDP43 Summit in Madison, Wisconsin, demonstrate that PET scans with ACI-19626 showed tracer uptake significantly higher in key regions of the brain in patients with ALS compared to healthy controls. Specifically, tracer uptake was higher in the brain stem and precentral gyrus, where TDP-43 pathology is expected to accumulate based on post-mortem neuropathology studies and on clinical symptoms. Previously reported data showed significantly higher tracer uptake in disease-relevant subcortical and cortical regions in patients with genetic frontotemporal dementia.

Reports Q1 revenue $1.12M, consensus $263,230. Andrea Pfeifer, CEO of AC Immune SA, commented: "The progress in our collaborations with Takeda and Eli Lilly reflect great confidence in our anti-Abeta active immunotherapy and Tau aggregation inhibitor small molecules, respectively. These have the potential to change the way we target the proteinopathies that drive Alzheimer's and other neurodegenerative diseases. This is further exemplified by the presentation of the interim results for ACI-7104 at AD/PD 2026 showing that our active immunotherapy targeting a-synuclein (a-syn) has the potential to modify disease pathology in Parkinson's disease. We also advanced our NLRP3 inhibitor ACI-19764 into clinical development, further demonstrating the power of AC Immune's technology to target the key pathways that contribute to neurodegeneration. We are now moving towards multiple value inflection points during 2026. These include Phase 2 data readouts on our active immunotherapies ACI-7104 and ACI-24, and initial results from the Phase 1 trial of ACI-19764 also anticipated this year."

AC Immune (ACIU) announced an agreement with Eli Lilly (LLY) to amend their 2018 license and collaboration agreement to research and develop Tau aggregation inhibitor small molecules for the potential treatment of Alzheimer's disease and other neurodegenerative diseases. The amendment continues the research and collaboration to cover development of new lead Tau Morphomer candidates and potential back-up compounds. Under this amendment, AC Immune will receive a CHF 10M upfront payment and a subsequent milestone payment with Phase 1 dosing, in addition to milestones announced in a prior amendment. AC Immune is eligible for further development, regulatory and commercial milestones of over CHF1.7B, plus tiered percentage royalty payments in the low double digits, as previously disclosed.